CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

• 1  Denton MD, Magee CC, Sayegh MH: Immunosuppressive strategies in transplantation. Lancet353(9158),1083–1091 (1999).
  Medline CASGoogle Scholar
• 2  Scott LJ, McKeage K, Keam SJ, Plosker GL: Tacrolimus: a further update of its use in management of organ transplantation. Drugs63(12),1247–1297 (2003).
  Medline CASGoogle Scholar
• 3  Staatz CE, Tett SE: Clinical pharmacokinetics and pharmacodynamics of tacrolimus in organ transplantation. Clin. Pharmacokinet.43(10),623–653 (2004).
  Medline CASGoogle Scholar
• 4  Jusko WJ, Thomson AW, Fung J et al.: Consensus document: therapeutic monitoring of tacrolimus (FK506). Ther. Drug Monit.17(6),606–614 (1995).
  Medline CASGoogle Scholar
• 5  Sandborn WJ, Lauson GM, Cody TJ et al.: Early cellular rejection after orthotopic liver transplantation correlates with low concentration of FK506 in hepatic tissue. Hepatology21(1),70–76 (1995).
  Medline CASGoogle Scholar
• 6  Sandborn WJ, Lawson GM, Krom RA, Wiesner RH: Hepatic allograft cyclosporine concentation is independent of the route of cyclosporine administration and correlates with the occurrence of early cellular rejection. Hepatology15(6),1086–1091 (1992).
  Medline CASGoogle Scholar
• 7  Capron A, Lerut J, Verbaandert C et al.: Validation of a liquid chromatography-mass spectrometric assay for tacrolimus in liver biopsies after hepatic transplantation: correlation with histopathologic staging of rejection. Ther. Drug Monit.29(3),340–348 (2007).▪ Provides evidence that tacrolimus concentrations in liver biopsy are related to graft outcome in the early phase after liver transplantation.
  Medline CASGoogle Scholar
• 8  MacPhee IA, Fredericks S, Tai T et al.: Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome P4503A5 and P-glycoprotein correlate with dose requirement. Transplantation74(11),1486–1489 (2002).
  Medline CASGoogle Scholar
• 9  Zheng HX, Webber S, Zeevi A et al.: Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am. J. Transplant.3(6),477–483 (2003).
  Medline CASGoogle Scholar
• 10  Anglicheau D, Vertuyft C, Laurent-Puig P et al.: Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J. Am. Soc. Nephrol.14(7),1889–1896 (2003).
  Medline CASGoogle Scholar
• 11  Hesselink DA, van Schaik RH, van der Heiden IP et al.: Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin. Pharmacol Ther.74(3),245–254 (2003).
  Medline CASGoogle Scholar
• 12  Thervet E, Anglicheau D, King B et al.: Impact of cytochrome P4503A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation76(8),1233–1235 (2003).
  Medline CASGoogle Scholar
• 13  Haufroid V, Mourad M, van Kerckhove V et al.: The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood concentrations in stable renal transplant patients. Pharmacogenetics14(3),147–154 (2004).
  Medline CASGoogle Scholar
• 14  Mourad M, Wallemacq P, De Meyer M et al.: Biotansformation enzymes and drug transporters pharmacogenetics in relation to immunosuppressive drugs: impact on pharmacokinetics and clinical outcome. Transplantation85(Suppl. 7),S19–S24 (2008).
  Medline CASGoogle Scholar
• 15  Elens L, Capron A, Kerckhove VV et al.: 1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation. Pharmacogenet. Genomics17(10),873–883 (2007).▪ Presents evidence that intrahepatic tacrolimus concentrations and graft outcome are related to the donor ABCB1 expression status after liver transplantation.
  Medline CASGoogle Scholar
• 16  Crettol S, Venetz JP, Fontana M et al.: Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients. Pharmacogenet. Genomics18(4),307–315 (2008).▪▪ Demonstrates the influence of the recipient ABCB1 gene-expression status on peripheral blood mononuclear cell ciclosporin concentrations after organ transplantation.
  Medline CASGoogle Scholar
• 17  Kandem LK, Streit F, Zanger UM et al.: Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin Chem.51(8),1374–1381 (2005).
  MedlineGoogle Scholar
• 18  Kuehl P, Zhang J, Lin Y et al.: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet.27(4),383–391 (2001).
  Medline CASGoogle Scholar
• 19  Hustert E, Habrel M, Burk O et al.: The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics11(9),773–779 (2001).
  Medline CASGoogle Scholar
• 20  Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T: Human P-glycoprotein transports cyclosporine A and FK506. J. Biol. Chem.268(9),6077–6080 (1993).
  Medline CASGoogle Scholar
• 21  Callaghan R, Crowley E, Potter S, Kerr ID: P-glycoprotein: so many ways to turn it on. J. Clin. Pharmacol.48(3),365–378 (2008).
  Medline CASGoogle Scholar
• 22  Coons JS, Wang YZ, Bines SD, Markham PN, Chong AS, Gebel HM: Multidrug resistance P-glycoprotein in human lymphocytes. Hum. Immunol.32(2),134–140 (1991).
  MedlineGoogle Scholar
• 23  Chaudhray PM, Mechetner EB, Roninson IB: Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood80(11),134–140 (1992).
  MedlineGoogle Scholar
• 24  Kim RB, Leake BF, Choo EF et al.: Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther.70(2),189–199 (2001).
  Medline CASGoogle Scholar
• 25  Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W: Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharamcogenet. Genomics15(10),693–704 (2005).
  Medline CASGoogle Scholar
• 26  Kimchy-Sarfaty C, Oh JM, Kim IW et al.: A ‘silent’ polymorphism in the MDR1 gene changes substrate specificity. Science315(5811),525–528 (2007).
  MedlineGoogle Scholar
• 27  Hesselink DA, van Gelder T, van Schaik RH: The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression? Pharmacogenomics6(4),323–337 (2005).
  CASGoogle Scholar
• 28  Woodahl EL, Yang Z, Bui T, Shen DD, Ho RJ: MDR1 G1199A polymorphism alters permeability of HIV protease inhibitors across P-glycoprotein-expressing epithelial cells. AIDS19(15),1617–1625 (2005).
  Medline CASGoogle Scholar
• 29  Woodahl EL, Yang Z, Bui T, Shen DD, Ho RJ: Multidrug resistance gene G1199A polymorphism alters efflux transport activity of P-glycoprotein. J. Pharmacol. Exp. Ther.310(3),1199–1207 (2004).▪ Reports that the G1199A polymorphism alters the efflux and transepithelial permeability of a fluorescent substrate and sensitivity to select cytotoxic agents, which may influence drug disposition and therapeutic efficacy of some P-glycoprotein substrates.
  Medline CASGoogle Scholar
• 30  Crouthamel MH, Wu D, Yang Z, Ho RJ: A novel MDR1 G1199A variant alters drug resistance and efflux transport activity of P-glycoprotein in recombinant Hek cells. J. Pharm. Sci.95(12),2767–2777 (2006).
  Medline CASGoogle Scholar
• 31  Marzolini C, Paus E, Buclin T, Kim RB: Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol Ther.75(1),13–33 (2004).
  Medline CASGoogle Scholar
• 32  Wallemacq P, Goffinet JS, O’Morchoe S et al.: Multi-site analytical evaluation of the Abbott ARCHITECT tacrolimus assay. Ther. Drug Monit.31(2),198–204 (2009).
  Medline CASGoogle Scholar
• 33  Capron A, Musuamba F, Latinne D et al.: Validation of a liquid chromatography mass spectrometric assay for tacrolimus in peripheral blood mononuclear cells. Ther. Drug Monit.31(2),178–186 (2009).
  Medline CASGoogle Scholar
• 34  Mai I, Perloff ES, Bauer S et al.: MDR1 haplotypes derived from exon 21 and 26 do not affect the steady state pharmacokinetics of tacrolimus in renal transplant patients. Br. J. Pharmacol.58(5),548–553 (2004).
  CASGoogle Scholar
• 35  Tsuchiya N, Satoh S, Tada H et al.: Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation78(8),1182–1187 (2004).
  Medline CASGoogle Scholar
• 36  Yu S, Wu L, Jin J et al.: Influence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation. Transplantation81(1),46–51 (2006).
  Medline CASGoogle Scholar
• 37  Wei-lin W, Jing J, Shu-sen Z et al.: Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients. Liver Transplant.12(5),775–780 (2006).
  MedlineGoogle Scholar
• 38  Goto M, Musuda S, Kiuchi T et al.: CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics14(7),471–478 (2004).
  Medline CASGoogle Scholar
• 39  Mourad M, Wallemacq P, De Meyer M et al.: The influence of genetic polymorphism of cytochrome P4503A5 and MDR1 (ABCB1) on the starting dose-adjusted tacrolimus through concentrations after kidney transplantation in relation to renal function. Clinical Chemistry Laboratories Medicine44(10),1192–1198 (2006).
  Medline CASGoogle Scholar
• 40  Hitzl M, Drescher S, van der Kuip H et al.: The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamnie 123 from CD56⁺ natural killer cells. Pharmacogenetics11(4),293–298 (2001).
  Medline CASGoogle Scholar
• 41  Drescher S, Schaeffeler E, Hitzl M et al.: MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br. J. Clin. Pharmacol.53(5),526–534 (2002).
  Medline CASGoogle Scholar
• 42  Fellay J, Marzolini C, Meaden ER et al.: Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: pharmacogenetics study. Lancet359(9300),30–36 (2002).
  Medline CASGoogle Scholar
• 43  Beysens AJ, Wijnene RM, Beuman GH, van der Heyden J, Kootstra G, van As H: FK506: monitoring in plasma or whole blood? Transplant. Proc.23(6),2745–2747 (1991).
  Medline CASGoogle Scholar
• 44  Machida M, Takahara S, Ishibashi M, Hayashi M, Sekihara T, Yamanaka H: Effect of temperature and haematocrit on plasma concentration of FK506. Transplant. Proc.23(6),2753–2754 (1991).
  Medline CASGoogle Scholar
• 45  Nagase K, Iwasaki K, Nozaki K, Noda K: Distribution and protein binding of FK506, a potent immunosuppressive macrolide lactone, in human blood and its uptake by erythrocytes. J. Pharm. Pharmacol.46(2),113–117 (1994).
  Medline CASGoogle Scholar